Filtered By:
Source: The Breast Journal
Cancer: Breast Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Comparison of Doctors' and Breast Cancer Patients' Perceptions of Docetaxel, Epirubicin, and Cyclophosphamide (TEC) Toxicity
Abstract
In Spain, around 26,000 cases of breast cancer are diagnosed each year, representing nearly 30% of all cancers in women. The aim this study was to compare the perceptions of nonhematologic toxicities after administration of a docetaxel, epirubicin, and cyclophosphamide (TEC) regimen between breast cancer patients and oncologists. Furthermore, the relationship between such adverse events and quality of life (QOL) was evaluated. Crossâsectional study carried out among 92 breast cancer patients who received TEC as neoadjuvant or adjuvant treatment. The main nonhematologic toxicities experienced by breast cancer pat...
Source: The Breast Journal - February 11, 2016 Category: Cancer & Oncology Authors: Juan Bayo, Blanca Prieto, Francisco Rivera Tags: Original Article Source Type: research
